CCL2 and glomerulonephritis: Given these findings, compensatory increases in CCL2 are not expected to occur during chronic treatment with QC/isoQC inhibitors in humans, a notion supported by the decreased serum, urine, and kidney CCL2 levels in PQ529-treated glomerulonephritis rats.